
Issuer/Manager	THE TRENDLINES GROUP LTD.
----------------	---------------------------

Securities	THE TRENDLINES GROUP LTD. – IL0011328858 – 42T
------------	--

Stapled Security	No
------------------	----

Announcement Title	General Announcement
--------------------	----------------------

Date & Time of Broadcast	21 June 2016 07:14:18
--------------------------	-----------------------

Status	New
--------	-----

Announcement Subtitle	OCS Expands Mandate of Trendlines Medical- Misgav Ltd. To Include Agtech Investments
-----------------------	---

Announcement Reference	SG160621OTHRFMOQ
------------------------	------------------

Submitted By (Co./Ind. Name)	Yosef Ron
------------------------------	-----------

Designation	Joint Company Secretary
-------------	-------------------------

Description	Please see attached.
-------------	----------------------

Attachments	Expansion of Trendlines Medical OCS Mandate
-------------	---



THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

**Office of the Chief Scientist Expands Mandate of Trendlines Medical -
Misgav Ltd. to include Agtech Investments**

The board of directors (the "**Board**") of The Trendlines Group Ltd. (the "**Company**" and, together with its subsidiaries and associated companies, the "**Group**") refers to the Company's announcement dated 16 March 2016 where it had submitted a request to the Office of the Chief Scientist of the Israel Ministry of Economy (the "**OCS**") to, *inter alia*, expand the mandate of its wholly owned subsidiary, Trendlines Medical - Misgav Ltd.'s ("**Trendlines Medical**") OCS incubator license (which was recently renewed through 31 December 2023) to include agtech investments (the "**Request**").

The Board wishes to announce that the OCS has on 2 June 2016 approved the Request and accepted Trendlines Medical's goal of establishing between 9 to 11 new portfolio companies a year (about 5 portfolio companies each in the medical device field and agtech field) (the "**OCS Approval**") (the official letter from the OCS was received by the Company on 20 June 2016).

The OCS Approval is conditional upon the submission to the OCS by Trendlines Medical of certain documentation as stipulated under the OCS Approval, which Trendlines Medical intends and anticipates to submit within the next two weeks.

The OCS Approval provides the Company continuing access to OCS financial support for new agtech investments, as have been made previously under the Company's wholly owned subsidiary, Trendlines Agtech - Mofet Ltd. ("**Trendlines Agtech**") incubator franchise. New agtech investments will be made under the Trendlines Medical incubator. The funding for agtech investments obtained under the OCS Approval is in addition to funding for new agtech activities originating from the US\$10 million Bayer Trendlines Ag Innovation Fund as announced by the Company on 18 April 2016. The Bayer Trendlines Ag Innovation Fund will invest in cutting edge, early-stage agricultural technologies and is managed by the Company

The OCS additionally approved the Company's request to co-locate its existing agtech investment activities with the Trendlines Medical incubator in the Company's headquarters in Northern Israel. This move will improve operational efficiencies and realize certain savings in overhead expenses through the sharing of the Group's marketing, development, and management support.

The OCS Approval will not have a material impact on the Group's earnings per share and net tangible assets per share for the financial year ending 31 December 2016.

BY ORDER OF THE BOARD

Yosef Ron
Joint Company Secretary
21 June 2016

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.